Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Enterprise Value (EV)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Current Enterprise Value (EV)

Abiomed Inc., current enterprise value calculation

Microsoft Excel
Current share price (P)
No. shares of common stock outstanding
US$ in thousands
Common equity (market value)1
Add: Class B Preferred Stock, $.01 par value; none issued and outstanding (per books)
Total equity
Add: Current portion of capital lease obligation (per books)
Add: Capital lease obligation, net of current portion (per books)
Total equity and debt
Less: Cash and cash equivalents
Less: Short-term marketable securities
Enterprise value (EV)

Based on: 10-K (reporting date: 2022-03-31).

1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×


Historical Enterprise Value (EV)

Abiomed Inc., EV calculation

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Share price1, 2
No. shares of common stock outstanding1
US$ in thousands
Common equity (market value)3
Add: Class B Preferred Stock, $.01 par value; none issued and outstanding (book value)
Total equity
Add: Current portion of capital lease obligation (book value)
Add: Capital lease obligation, net of current portion (book value)
Total equity and debt
Less: Cash and cash equivalents
Less: Short-term marketable securities
Enterprise value (EV)

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 Closing price as at the filing date of Abiomed Inc. Annual Report.

3 2022 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×


Equity and Market Value Trends
Over the analyzed period, the common equity, which is reflected both as common equity (market value) and total equity, exhibited significant fluctuations. Initially, between March 31, 2017, and March 31, 2018, there was a substantial increase from approximately $5.95 billion to $17.54 billion. This sharp rise was followed by a decline to about $11.85 billion by March 31, 2019, and further decreased to approximately $8.83 billion by March 31, 2020. The equity value rebounded to $12.68 billion as of March 31, 2021, but then declined again to around $10.74 billion by March 31, 2022. This pattern indicates volatility in equity valuation with a notable peak in 2018 and variability in subsequent years.
Total Equity and Debt
The figures for total equity and debt mirror those of total equity and common equity, suggesting either a minimal or nonexistent debt component during the periods reviewed. The total equity and debt decreased consistently from the high point in 2018 through 2022, aligning with trends observed in the equity values.
Enterprise Value (EV) Movements
Enterprise value followed a similar trend to equity values but was consistently slightly lower in absolute terms. Starting at approximately $5.74 billion in March 2017, EV surged to about $17.18 billion in March 2018. It then decreased steadily each year to reach roughly $9.98 billion by March 2022. The EV's trajectory reflects changes in market capitalization minus cash and adding debt, which in this case appears closely related to total equity movements given the lack of significant debt. The general decrease following 2018 points to a contraction in overall enterprise valuation over time.
Overall Observations
The financial data suggest that the company experienced a peak in market valuation and enterprise value around 2018, followed by a period of decline and partial recovery. The absence of divergence between total equity, common equity (market value), and total equity and debt values indicates limited leverage impact during this timeframe. The fluctuations in valuation could be attributed to changes in market conditions, operational performance, or investor sentiment. The decline in enterprise value and equity after 2018 signifies challenges in maintaining the high valuation achieved that year.